AngioLab, Inc. Logo

AngioLab, Inc.

Develops anti-angiogenic therapeutics and foods for angiogenesis-related diseases.

251280 | KO

Overview

Corporate Details

ISIN(s):
KR7251280004
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노3로 65, 대전광역시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

AngioLab, Inc. is a biotechnology company established in 1999 that specializes in the research and development of therapeutics based on angiogenesis inhibition. The company develops pharmaceuticals and health functional foods designed to treat a variety of angiogenesis-related diseases. Its core technology focuses on the discovery and application of anti-angiogenic and matrix metalloproteinase (MMP) inhibitors. AngioLab manages a pipeline of drug candidates, advancing them through clinical trials to create novel treatments for conditions driven by abnormal blood vessel formation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 63.7 KB
2025-09-10 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.7 KB
2025-07-17 00:00
Share Issue/Capital Change
기타주요경영사항(자율공시) (전환우선주의 보통주 전환)
Korean 7.8 KB
2025-04-23 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.7 KB
2025-04-08 00:00
Share Issue/Capital Change
기타주요경영사항(자율공시) (전환우선주의 보통주 전환)
Korean 7.8 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.8 KB
2025-03-20 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.9 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 9.6 KB
2025-03-18 00:00
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
Korean 342.5 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 261.5 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.8 KB
2025-03-07 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 19.9 KB
2025-03-07 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 18.7 KB
2025-03-04 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 42.6 KB
2025-02-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.1 KB

Automate Your Workflow. Get a real-time feed of all AngioLab, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AngioLab, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AngioLab, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Material Group inc. Logo
A professional services firm offering PR consulting, marketing, and brand strategy.
Japan
156A
Medesis Pharma S.A. Logo
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
France
ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.
Poland
MDB
Medpace Holdings, Inc. Logo
Global CRO providing full-service clinical development to biotech, pharma & medical device industries.
United States of America
MEDP
Develops biomarker-based precision therapies for oncology and other incurable diseases.
South Korea
235980
Medrx Co.,Ltd. Logo
Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.
Japan
4586
Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan
7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden
IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D

Talk to a Data Expert

Have a question? We'll get back to you promptly.